LOG IN
SIGN UP
MARKET
CRBP
CRBP
Corbus Pharmaceu
NASDAQ
Real-time Quotes | Nasdaq Last Sale
0.3024
0.0000
0.00%
Opening 09:41 05/26 EDT
OPEN
0.3000
PREV CLOSE
0.3024
HIGH
0.3088
LOW
0.3000
VOLUME
18.56K
TURNOVER
5.16K
52 WEEK HIGH
2.290
52 WEEK LOW
0.2080
MARKET CAP
37.88M
P/E (TTM)
-0.9394
1D
5D
1M
3M
1Y
5Y
Cannabis Stock Gainers And Losers From May 19, 2022
GAINERS: Zynerba Pharmaceuticals (NASDAQ:ZYNE) shares closed up 7.42% at $0.99
Benzinga · 6d ago
Marijuana Stock Movers For May 18, 2022
GAINERS: Item 9 Labs (OTC:INLB) shares closed up 21.21% at $1.00
Benzinga · 05/18 20:36
BRIEF-Corbus Pharmaceuticals Entered Into Binding Term Sheet With Venn Therapeutics To Resolve Claims By Venn Against Co
reuters.com · 05/17 22:13
73 Biggest Movers From Yesterday
Gainers AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) shares jumped 65.9% to close at $2.77 on Monday after gaining around 10% on Friday.
Benzinga · 05/17 08:49
Corbus Presents Latest Preclinical Data For CRB-601 At The New York Academy Of Sciences Frontiers In Cancer Immunotherapy Conference
CRB-601 is a highly potent and selective anti-αvβ8 integrin monoclonal antibody designed to block the activation of TGFb in the local tumor microenvironment Additional non-clinical data
Benzinga · 05/11 12:13
Corbus Presents Latest Preclinical Data for CRB-601 at the New York Academy of Sciences Frontiers in Cancer Immunotherapy Conference
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, announced that new preclinical data for CRB-601 are being presented today in an oral presentation at the New York Academy of Sciences (NYAS) Frontiers ...
PR Newswire · 05/11 12:00
Corbus Pharmaceuticals: Q1 Earnings Insights
Corbus Pharmaceuticals (NASDAQ:CRBP) reported its Q1 earnings results on Tuesday, May 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Benzinga · 05/10 14:19
Corbus Pharmaceuticals (CRBP) Reports Q1 Loss, Lags Revenue Estimates
Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of 11.11% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/10 13:25
No Data
Learn about the latest financial forecast of CRBP. Analyze the recent business situations of Corbus Pharmaceu through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 3 analysts
Hold
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
0.00%Strong Buy
33.33%Buy
66.67%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CRBP stock price target is 1.980 with a high estimate of 3.000 and a low estimate of 0.9600.
Current 0.3000
EPS
Actual
Estimate
-0.12-0.09-0.06-0.03
Institutional Holdings
Institutions: 161
Institutional Holdings: 51.04M
% Owned: 40.75%
Shares Outstanding: 125.26M
TypeInstitutionsShares
Increased
27
1.90M
New
14
584.35K
Decreased
19
1.85M
Sold Out
18
786.11K
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.26%
Pharmaceuticals & Medical Research
+0.23%
Key Executives
Non-Executive Chairman/Independent Director
Alan Holmer
Chief Executive Officer/Director
Yuval Cohen
Chief Financial Officer/IR Contact Officer
Sean Moran
Chief Operating Officer
Craig Millian
Chief Scientific Officer
Rachael Brake
Independent Director
Avery Catlin
Independent Director
Rachelle Jacques
Independent Director
John Jenkins
Independent Director
Peter Salzmann
No Data
No Data
About CRBP
Corbus Pharmaceuticals Holdings, Inc. is a Phase-III, clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer. It develops a diverse pipeline of drug candidates across programs, including small molecules as well as biologics. The Company's lead product candidate, Lenabasum, a novel, synthetic, oral, cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation, limit fibrosis and support tissue repair. Lenabasum is in clinical development for treatment of autoimmune diseases. It is evaluating lenabasum and is in a Phase III study in dermatomyositis, as well as a Phase II study in systemic lupus erythematosus (SLE). It designs cannabinoid receptor type 1 (CB1) inverse agonists to normalize metabolic abnormalities or limit inflammation and fibrosis.
Webull offers kinds of Corbus Pharmaceuticals Holdings Inc stock information, including NASDAQ:CRBP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRBP stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading CRBP stock methods without spending real money on the virtual paper trading platform.